Taken together, while multiple approaches are currently being tested in preclinical and clinical trials for the reactivation of p53 in cancer cells [49,50,51,52,53,54,55,64,65], drugs for the reactivation of p53 have not been approved yet for treating cancer patients. The gene discussed is TP53; the disease is cancer.